| Bioactivity | Pegbelfermin (BMS-986036) is a polyethylene glycol-modified (PEGylated) analogue of human fibroblast growth factor 21 (FGF21). Pegbelfermin can be used for the research of nonalcoholic steatohepatitis (NASH)[1][2]. |
| In Vivo | Pegbelfermin 在动物模型中改善 NASH 和纤维化的组织学特征[1]。Pegbelfermin 显着降低肝脂肪变性和纤维化生物标志物 N 端 III 型胶原蛋白前肽 (PRO-C3)，并改善代谢参数和肝损伤生物标志物[1]。Pegbelfermin 降低了负责二级胆汁酸合成的基因的表达[1]。 |
| Name | Pegbelfermin |
| CAS | 2089039-22-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Luo Y, et al. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis. JHEP Rep. 2021 Nov 12;4(1):100392. [2]. Thompson KE, et al. Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys. Toxicol Appl Pharmacol. 2021 Oct 1;428:115673. |